Loading...
XNYSABBV
Market cap310bUSD
Dec 20, Last price  
175.72USD
1D
2.45%
1Q
-9.17%
Jan 2017
180.61%
IPO
404.51%
Name

Abbvie Inc

Chart & Performance

D1W1MN
XNYS:ABBV chart
P/E
63.85
P/S
5.72
EPS
2.75
Div Yield, %
3.39%
Shrs. gr., 5y
2.78%
Rev. gr., 5y
10.65%
Revenues
54.32b
-6.44%
14,214,196,00015,638,000,00017,443,951,00018,380,000,00018,790,000,00019,960,000,00022,859,000,00025,638,000,00028,216,000,00032,753,000,00033,266,000,00045,804,000,00056,197,000,00058,054,000,00054,318,000,000
Net income
4.86b
-58.91%
4,636,515,0004,178,000,0003,433,128,0005,275,000,0004,128,000,0001,774,000,0005,144,000,0005,953,000,0005,309,000,0005,687,000,0007,882,000,0004,616,000,00011,542,000,00011,836,000,0004,863,000,000
CFO
22.84b
-8.44%
5,367,336,0004,976,000,0006,246,960,0006,345,000,0006,267,000,0003,549,000,0007,535,000,0007,041,000,0009,960,000,00013,427,000,00013,324,000,00017,588,000,00022,777,000,00024,943,000,00022,839,000,000
Dividend
Jan 15, 20251.64 USD/sh
Earnings
Jan 31, 2025

Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
URL
https://www.abbvie.com/
IPO date
Jan 02, 2013
Employees
50,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
54,318,000
-6.44%
58,054,000
3.30%
56,197,000
22.69%
Cost of revenue
28,957,000
39,184,000
36,879,000
Unusual Expense (Income)
NOPBT
25,361,000
18,870,000
19,318,000
NOPBT Margin
46.69%
32.50%
34.38%
Operating Taxes
1,377,000
1,632,000
1,440,000
Tax Rate
5.43%
8.65%
7.45%
NOPAT
23,984,000
17,238,000
17,878,000
Net income
4,863,000
-58.91%
11,836,000
2.55%
11,542,000
150.04%
Dividends
(10,539,000)
(10,043,000)
(9,261,000)
Dividend yield
3.84%
3.50%
3.85%
Proceeds from repurchase of equity
(1,792,000)
(1,225,000)
310,000
BB yield
0.65%
0.43%
-0.13%
Debt
Debt current
7,191,000
4,136,000
12,495,000
Long-term debt
52,956,000
59,906,000
64,927,000
Deferred revenue
3,720,000
6,595,000
Other long-term liabilities
28,607,000
30,655,000
22,106,000
Net debt
47,027,000
54,572,000
67,315,000
Cash flow
Cash from operating activities
22,839,000
24,943,000
22,777,000
CAPEX
(777,000)
(695,000)
(787,000)
Cash from investing activities
(2,009,000)
(623,000)
(2,344,000)
Cash from financing activities
(17,222,000)
(24,803,000)
(19,039,000)
FCF
23,930,000
17,413,000
18,016,000
Balance
Cash
12,816,000
9,229,000
9,830,000
Long term investments
304,000
241,000
277,000
Excess cash
10,404,100
6,567,300
7,297,150
Stockholders' equity
(3,250,000)
2,636,000
274,000
Invested Capital
105,359,000
108,577,000
120,547,000
ROIC
22.42%
15.05%
14.34%
ROCE
24.37%
16.64%
15.60%
EV
Common stock shares outstanding
1,773,000
1,778,000
1,777,000
Price
154.97
-4.11%
161.61
19.36%
135.40
26.36%
Market cap
274,761,810
-4.38%
287,342,580
19.42%
240,605,800
34.22%
EV
321,825,810
341,947,580
307,948,800
EBITDA
34,059,000
27,337,000
27,839,000
EV/EBITDA
9.45
12.51
11.06
Interest
1,669,000
2,230,000
2,384,000
Interest/NOPBT
6.58%
11.82%
12.34%